169 related articles for article (PubMed ID: 15651062)
1. In vivo imaging of retinoic acid receptor beta2 transcriptional activation by the histone deacetylase inhibitor MS-275 in retinoid-resistant prostate cancer cells.
Qian DZ; Ren M; Wei Y; Wang X; van de Geijn F; Rasmussen C; Nakanishi O; Sacchi N; Pili R
Prostate; 2005 Jun; 64(1):20-8. PubMed ID: 15651062
[TBL] [Abstract][Full Text] [Related]
2. Epigenetic modulation of retinoic acid receptor beta2 by the histone deacetylase inhibitor MS-275 in human renal cell carcinoma.
Wang XF; Qian DZ; Ren M; Kato Y; Wei Y; Zhang L; Fansler Z; Clark D; Nakanishi O; Pili R
Clin Cancer Res; 2005 May; 11(9):3535-42. PubMed ID: 15867257
[TBL] [Abstract][Full Text] [Related]
3. Epigenetic patterns of the retinoic acid receptor beta2 promoter in retinoic acid-resistant thyroid cancer cells.
Cras A; Darsin-Bettinger D; Balitrand N; Cassinat B; Soulié A; Toubert ME; Delva L; Chomienne C
Oncogene; 2007 Jun; 26(27):4018-24. PubMed ID: 17213810
[TBL] [Abstract][Full Text] [Related]
4. Combination of retinoid and histone deacetylase inhibitor produced an anti-tumor effect in cutaneous T-cell lymphoma by restoring tumor suppressor gene, retinoic acid receptorβ2, via histone acetylation.
Kato Y; Egusa C; Maeda T; Tsuboi R
J Dermatol Sci; 2016 Jan; 81(1):17-25. PubMed ID: 26596218
[TBL] [Abstract][Full Text] [Related]
5. Antitumor activity of the histone deacetylase inhibitor MS-275 in prostate cancer models.
Qian DZ; Wei YF; Wang X; Kato Y; Cheng L; Pili R
Prostate; 2007 Aug; 67(11):1182-93. PubMed ID: 17520666
[TBL] [Abstract][Full Text] [Related]
6. Combination of phenylbutyrate and 13-cis retinoic acid inhibits prostate tumor growth and angiogenesis.
Pili R; Kruszewski MP; Hager BW; Lantz J; Carducci MA
Cancer Res; 2001 Feb; 61(4):1477-85. PubMed ID: 11245454
[TBL] [Abstract][Full Text] [Related]
7. The histone deacetylase inhibitor NVP-LAQ824 inhibits angiogenesis and has a greater antitumor effect in combination with the vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584.
Qian DZ; Wang X; Kachhap SK; Kato Y; Wei Y; Zhang L; Atadja P; Pili R
Cancer Res; 2004 Sep; 64(18):6626-34. PubMed ID: 15374977
[TBL] [Abstract][Full Text] [Related]
8. Synergistic in vivo antitumor effect of the histone deacetylase inhibitor MS-275 in combination with interleukin 2 in a murine model of renal cell carcinoma.
Kato Y; Yoshimura K; Shin T; Verheul H; Hammers H; Sanni TB; Salumbides BC; Van Erp K; Schulick R; Pili R
Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4538-46. PubMed ID: 17671140
[TBL] [Abstract][Full Text] [Related]
9. Enhancement of xenograft tumor radiosensitivity by the histone deacetylase inhibitor MS-275 and correlation with histone hyperacetylation.
Camphausen K; Scott T; Sproull M; Tofilon PJ
Clin Cancer Res; 2004 Sep; 10(18 Pt 1):6066-71. PubMed ID: 15447991
[TBL] [Abstract][Full Text] [Related]
10. Embryonal carcinoma cell lines stably transfected with mRARbeta2-lacZ: sensitive system for measuring levels of active retinoids.
Sonneveld E; van den Brink CE; van der Leede BJ; Maden M; van der Saag PT
Exp Cell Res; 1999 Aug; 250(2):284-97. PubMed ID: 10413584
[TBL] [Abstract][Full Text] [Related]
11. Antitumor effect of the histone deacetylase inhibitor LAQ824 in combination with 13-cis-retinoic acid in human malignant melanoma.
Kato Y; Salumbides BC; Wang XF; Qian DZ; Williams S; Wei Y; Sanni TB; Atadja P; Pili R
Mol Cancer Ther; 2007 Jan; 6(1):70-81. PubMed ID: 17237267
[TBL] [Abstract][Full Text] [Related]
12. MS-27-275, an inhibitor of histone deacetylase, has marked in vitro and in vivo antitumor activity against pediatric solid tumors.
Jaboin J; Wild J; Hamidi H; Khanna C; Kim CJ; Robey R; Bates SE; Thiele CJ
Cancer Res; 2002 Nov; 62(21):6108-15. PubMed ID: 12414635
[TBL] [Abstract][Full Text] [Related]
13. Endogenous reactivation of the RARbeta2 tumor suppressor gene epigenetically silenced in breast cancer.
Sirchia SM; Ren M; Pili R; Sironi E; Somenzi G; Ghidoni R; Toma S; Nicolò G; Sacchi N
Cancer Res; 2002 May; 62(9):2455-61. PubMed ID: 11980632
[TBL] [Abstract][Full Text] [Related]
14. Sulfonamide anilides, a novel class of histone deacetylase inhibitors, are antiproliferative against human tumors.
Fournel M; Trachy-Bourget MC; Yan PT; Kalita A; Bonfils C; Beaulieu C; Frechette S; Leit S; Abou-Khalil E; Woo SH; Delorme D; MacLeod AR; Besterman JM; Li Z
Cancer Res; 2002 Aug; 62(15):4325-30. PubMed ID: 12154036
[TBL] [Abstract][Full Text] [Related]
15. Evidence of epigenetic changes affecting the chromatin state of the retinoic acid receptor beta2 promoter in breast cancer cells.
Sirchia SM; Ferguson AT; Sironi E; Subramanyan S; Orlandi R; Sukumar S; Sacchi N
Oncogene; 2000 Mar; 19(12):1556-63. PubMed ID: 10734315
[TBL] [Abstract][Full Text] [Related]
16. A novel retinoic acid receptor beta isoform and retinoid resistance in lung carcinogenesis.
Petty WJ; Li N; Biddle A; Bounds R; Nitkin C; Ma Y; Dragnev KH; Freemantle SJ; Dmitrovsky E
J Natl Cancer Inst; 2005 Nov; 97(22):1645-51. PubMed ID: 16288117
[TBL] [Abstract][Full Text] [Related]
17. Multiple Molecular pathways explain the anti-proliferative effect of valproic acid on prostate cancer cells in vitro and in vivo.
Shabbeer S; Kortenhorst MS; Kachhap S; Galloway N; Rodriguez R; Carducci MA
Prostate; 2007 Jul; 67(10):1099-110. PubMed ID: 17477369
[TBL] [Abstract][Full Text] [Related]
18. An EGF receptor inhibitor induces RAR-beta expression in breast and ovarian cancer cells.
Grunt TW; Puckmair K; Tomek K; Kainz B; Gaiger A
Biochem Biophys Res Commun; 2005 Apr; 329(4):1253-9. PubMed ID: 15766561
[TBL] [Abstract][Full Text] [Related]
19. Effects of histone deacetylase inhibitors on the Ah receptor gene promoter.
Garrison PM; Rogers JM; Brackney WR; Denison MS
Arch Biochem Biophys; 2000 Feb; 374(2):161-71. PubMed ID: 10666294
[TBL] [Abstract][Full Text] [Related]
20. Quantitative promoter hypermethylation analysis of cancer-related genes in salivary gland carcinomas: comparison with methylation-specific PCR technique and clinical significance.
Lee ES; Issa JP; Roberts DB; Williams MD; Weber RS; Kies MS; El-Naggar AK
Clin Cancer Res; 2008 May; 14(9):2664-72. PubMed ID: 18451230
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
